Prokarium Ltd, Release: New Vaccine For Chlamydia To Use Synthetic Biology
Summary
Symptoms can be serious including pelvic inflammatory disease that can lead to infertility and, in children infected by their mothers, even blindness.According to Dr Ted Fj\xe4llman, CEO of Prokarium, the new vaccine uses synthetic biology to make the first safe and effective Chlamydia vaccine since the 1960s when conventional methods revealed unacceptable side effects and clinical efforts were abandoned. Dr Steve Chatfield, Chairman of Prokarium and former Executive Director of the UK Health Protection Agency, says: This SynbiCITE funding allows us to test a vaccine against the one of the worlds most serious sexually transmitted infections. This endeavour, amongst others, has also enabled us to attract Dr Allan Jarvis, former Vice President of Corporate Development of Sanofi Pasteur to Prokariums Board of Directors. Prokarium is funded by Flerie Invest AB, it has a research collaboration with big pharma on C.difficile and is currently seeking further investment to take one or more of its candidate vaccines into the clinic.About SynbiCITEhttp://synbicite.comSynbiCITE is a pioneering Innovation and Knowledge Centre (IKC) dedicated to promoting the adoption and use of synthetic biology by industry. The IKC is an internationally recognised lead centre in industrialising synthetic biology research giving the UK a globally renowned national resource of interacting partners from across the UKs leading academic institutions, industry and business.SynbiCITE is focused at Imperial College London and is, with our partners, accelerating the commercialisation of world-class science and the emerging technologies encompassed by synthetic biology into new products, tools, processes and services.